$547.65▴ 0.57%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Vertex Pharmaceuticals Incorporated's earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days8 articles
2 bullish6 neutral0 bearish
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?
Vertex Posts Positive Phase II Data on Kidney Disease Drug
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYHAerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board
- SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down